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Hydrodynamic gene delivery (HGD) has emerged as an effective and safe method for 
transfecting liver hepatocytes in vivo, and has potential for gene therapy of liver fibrosis. The 
objective of this study was to evaluate the effectiveness and safety of HGD using CCl4 induced 
fibrotic liver in rats as a model. I demonstrated that there is a progressive reduction of efficiency 
of HGD in rats with increasing severity of liver fibrosis. Using a reporter plasmid containing 
luciferase gene, we showed over 2,000-fold decrease in luciferase activity in the liver with 
advanced fibrosis compared to that of control animals. Reduction in reporter gene expression in 
fibrotic liver was correlated to lower copy number of plasmid DNA and less amount of luciferase 
mRNA in the liver. Microscopy analysis revealed significant accumulation of collagen fibers in 
the boundary of liver lobules and thickened hepatic sinusoidal endothelium. The morphological 
changes in fibrotic liver are associated with restriction of flow-through across the liver of DNA 
solution hydrodynamically injected and are responsible for the reduced gene delivery efficiency 
of the hydrodynamic procedure. Results from electrocardiogram and serum biochemistry show 
no difference between the control and fibrotic animals undergone HGD. These results suggest 
that the HGD is a safe method for gene transfer in animals with liver fibrosis but the 
effectiveness of gene delivery decreases with increase of severity of fibrosis. Future work should 
focus on adjustment of injection parameters (DNA dose, injection volume, injection speed) for 
optimal gene delivery to fibrotic liver. 
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1.0 INTRODUCTION 
 
Liver fibrosis, or cirrhosis, featured by excessive accumulation of extracellular collagen fibers 
are characteristics of chronic liver diseases that affect millions of people worldwide.1-4 The 
accumulated matrix proteins distort the hepatic architecture and eventually result in liver failure 
if the fibrogenic process is not controlled properly. Anti-fibrotic gene therapy has been 
demonstrated to be helpful in controlling fibrogenesis,2, 5-9 but the effective and safe gene 
delivery remains as a critical issue for therapeutic success.3, 6 The prevailing viral and non-viral 
vectors for hepatic gene transfer are less than ideal due to concerns of low delivery efficiency of 
nonviral vectors, and rapid inactivation, immunogenicity, insertional mutagenesis, and high 
preparation cost of viral vectors.10-12 These issues significantly limit the applicability of these 
methods for gene therapy of liver fibrosis. There is a significant need for a new method for 
intrahepatic gene delivery. 
 
In recent years, hydrodynamic gene delivery (HGD) has emerged as an effective and safe method 
for intrahepatic gene delivery in rodents and large animals as well.11, 13 HGD relies on a rapid 
intravascular injection of large volume of DNA solution into the tail vein of rodents or hepatic 
vein in large animals to achieve enhanced permeability of liver sinusoidal endothelium and 
plasma membrane of hepatocytes. Although seemingly harsh, the HGD is proven to be safe and 
has been widely employed for gene therapy studies (for recent reviews, see10-11). Results from 
repeated HGD into mice showed no difference in gene delivery efficiency, no immune response 
to plasmid DNA, and no inactivation of gene expression by preexisting immunity that is seen in 
viral vector-mediated gene delivery.11, 13-14 The marked effectiveness, safety and simplicity 
present the HGD as a promising method for gene delivery to fibrotic liver. 
 
Despite a large number of studies in the literature documenting the effectiveness and safety of 
HGD in healthy animals,11 little is known about its effectiveness and safety in animals with liver 
fibrosis. In this study, we systematically evaluated the effect of the severity of liver fibrosis on 
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delivery efficiency and safety of HGD in fibrotic rats. We demonstrated that the HGD is less 
effective in fibrotic liver although being safe. Results from mechanistic studies suggest that the 
reduced efficiency is due to the enriched extracellular matrix that blocks the expansion of liver 
sinusoids. These results suggest that future efforts for improving HGD effectiveness in fibrotic 
liver be directed to increasing gene delivery efficiency by adjusting hydrodynamic parameters 
including plasmid concentration, injection volume, and injection speed. 
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2.0 MATERIALS AND METHODS 
 
2.1 Plasmids, reagents and animals 
The pCMV-Luc reporter plasmid was constructed by inserting firefly luciferase cDNA between 
the Hind III and Xba I restriction sites within the multiple cloning site of pcDNA3 backbone 
(Invitrogen, USA), and propagated in the E. coli DH5α. The plasmid was purified using the 
CsCl-ethidium bromide gradient centrifugation15 and stored in TE buffer (10 mM Tris HCl, 1 
mM ethylene diaminetetraacetic acid (EDTA), pH 8.0) at -20oC until use. The quality and 
quantity of the purified plasmid DNA was evaluated by absorbency at 260 and 280 nm and gel 
electrophoresis on 1% agrose gel in Tris/Borate/EDTA buffer. CCl4 and olive oil were purchased 
from Sigma-Aldrich. Male Sprague Dawley rats weighing 50-70 g were purchased from Charles 
River and used to establish liver fibrosis model.  
 
2.2 Establishment of liver fibrosis 
Rats with free access to standard chow and water were injected intraperitoneally with 0.2 ml/100 
g sterile CCl4 in a 1:1 ratio (v/v) with olive oil twice weekly for 2 weeks, followed by the same 
dosing interval with reduced dose at 0.1 ml/100 g for 2 to 6 weeks. Olive oil was used instead of 
CCl4 for the treatment of control animals.  
 
2.3 Examination of severity of fibrosis and HGD effectiveness in fibrotic liver 
On the 6th day after the last CCl4 injection, the control and CCl4 treated rats were randomly 
selected, i.p. anesthetized using 2,2,2-tribromoethanol (TBE; concentration, 0.016 g/ml in 0.9% 
saline; dose, 1.25 ml/100g body weight), and injected from tail vein with 7.5% body weight of 
saline containing pCMV-Luc plasmid (10 μg/ml) within 7-10 sec (n=3-5), by using a 21-gauge 
winged infusion set (Terumo, Japan). Nine hours after injection, the liver was harvested and 
subjected to examination of fibrosis severity and HGD effectiveness. The fibrosis severity was 
examined by Masson’s Trichrome and H&E staining. The right lateral lobe of each animal was 
removed 9 hrs after plasmid injection and immersed in 10% formalin for 1 week. Tissue 
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embedding, sectioning (5 µm), and Masson’s Trichrome and H&E staining were performed by 
staff members in the Research Histology Lab of the University of Pittsburgh Department of 
Pathology. The stained sections were then observed and photographed using a regular light 
microscope. The average luciferase activity of left lateral lobe, left medial lobe and right lateral 
lobe was used to determine HGD effectiveness. For luciferase assay, around 200 mg of liver 
sample were collected and thoroughly homogenized using a tissue Tearor for 30 s at its 
maximum speed, and the tissue homogenates were centrifuged for 10 min at 13,000×g at 4°C. 
The supernatant was further diluted tenfold using HEPES buffer and 10 μl of supernatant was 
mixed with 100 μl of luciferase substrates, and the luciferase activity was measured in a 
luminometer (AutoLumant LB 953, EG&G, Salem, MA) for 10 s. Protein concentration of the 
supernatant was determined by using Coomassie Blue assay. Luciferase level was expressed as 
the relative light unit per mg of extracted proteins. 
 
2.4 Determination of luciferase mRNA level and the copy number of plasmid in liver 
samples 
For the determination of luciferase mRNA level, the liver total RNA was extracted using Trizol 
reagent (Invitrogen) and the reverse transcription was performed using SuperScript III first-
strand cDNA synthesis kit (Invitrogen) with oligo(dT)20 to initiate reverse transcription. The 
primers for the real-time PCR were cLuc-F: 5’-GCCTGAAGTCTCTGATTAAGT-3’; cLuc-R: 
5’-ACACCTGCGTCGAAGT-3’. The quantities of luciferase mRNA transcripts per µg of total 
RNA in control and CCl4-treated rats were derived from the standard curve established by q-PCR 
using serially diluted known amount of pCMV-Luc plasmid. For determination of plasmid copy 
number, liver DNA was extracted by using the DNeasy Blood and Tissue Kit (Qiagen). The 
primers for real-time PCR were derived from neomycin resistance gene in plasmid backbone as 
Neomycin-F: 5’-TGCTCCTGCCGAGAAAGTAT-3’; Neomycin-R: 5’- 
GCTCTTCGTCCAGATCATCC-3’. The copy number of plasmid DNA per µg of total DNA in 
control and CCl4-treated rats were extrapolated from a standard curve. Real-time PCR 
experiments were performed using StepOnePlus systems (Applied Biosystems) with the 
following parameters: an initial denaturation at 95ºC for 10 min, followed by 40 cycles at 94ºC 
for 15 sec and 60ºC for 1 min. SyBrGreen (Applied Biosystems) was used to indicate target gene 
amplification and the specificity of amplification was examined by automated melting curve 
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analysis. 
 
2.5 Measurement of IVC and PV pressure during hydrodynamic injection 
The measurement of intravascular pressure was performed as described by Suda et al.16 with 
modifications. An abdominal incision was made in TBE-anesthetized animals and the internal 
organs in the peritoneal cavity were exposed. A pressure detector was inserted into the catheter at 
the IVC or PV through a three-way connector and connected to a transducer for the real-time 
measurement of the pressure change during the hydrodynamic injection of saline.  
 
2.6 Scanning and transmission electron microscopy 
For both scanning and transmission microscopy (SEM and TEM), PBS containing 2.5% 
glutaraldehyde was hydrodynamically injected through the IVC into the anesthetized animals, 
and the liver was removed immediately after injection and immersed in the same fixative 
overnight for SEM, or immersed for 3 days for TEM. Small samples of the liver were processed 
for TEM as described by Stolz et al.17 For SEM, sections from fixed liver samples were further 
washed with PBS and processed with osmium tetroxide and ethanol according to Suda et al.16 
The processed sections were mounted onto aluminum stubs, sputter-coated with 3.5 nm 
gold/palladium and viewed under a JEOL JSM-6330F scanning electron microscope, and 
photographed by using the interactive Quartz PCI image system. 
 
2.7 Electrocardiogram and serum biochemistry assay 
ECG on the CCl4-treated rats was monitored using the BIOPAC 100C ECG detection system 
(Santa Barbara, CA) as described by Zhou et al.14 The Monopol needle electrodes (EL452, 15 
mm TP) were inserted subcutaneously into the chest area of an anesthetized rat. The ECG waves 
were recorded and processed using the Acqcknowledge software before, during, and after 
hydrodynamic injection. For serum biochemistry assay, serum samples were collected from the 
control and CCl4-treated rats by clipping the tail before and 9 hr after hydrodynamic injection 
and subjected to the automated analysis using an IDEXX VetTest Chemistry Analyzer 
(Westbrook, ME). 
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2.8 Statistical methods 
Differences were statistically evaluated by Student’s t-test between two groups. A p-value of 
0.05 is considered as statistically significant, and 0.01 as very significant. 
7 
 
 
 
3.0 RESULTS 
 
3.1 Establishment of liver fibrosis in rats  
Liver fibrosis was established by weekly intraperitoneal injection of CCl4 according to a 
previously published procedure.18 Figure 1 shows a time dependent, progressive accumulation of 
extracellular matrix proteins in the liver. In control animals treated with carrier solution (olive oil) 
for 8 weeks (Figure 1A), no collagen fibers are visible by Masson’s trichrome staining compared 
to an enhanced level of collagen fibers (blue bands) at the edge of the liver lobules 4 weeks after 
CCl4 treatment (Figure 1B). In the CCl4 treated rats for 8 weeks, a network of fibrotic tissue 
resulting from extensive portal-portal bridging and occasional portal-central bridging are evident 
(Figure 1C). These results suggest that moderate and advanced liver fibrosis was successfully 
developed in CCl4-treated rats. Figures 1D-1F are H&E staining of liver samples from control 
(Figure 1D), CCl4 treated for 4 weeks (Figure 1E), or 8 weeks (Figure 1F), exhibiting no visible 
damage at cellular level, but with enriched matrix protein near the portal site of CCl4 treated 
animal for 8 weeks (Figure 1F).   
 
D F
A B C
E
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Figure 1. Histochemistry of the Liver. Liver sections from rats treated with either 
olive oil or CCl4 were Masson’s trichrome stained for collagen (A, B, C), or H&E 
(D, E, F) for cellular structure. A and D represent the structures of control animals 
treated with olive oil for 8 weeks. B and E represent the structures of animals 
treated with CCl4 for 4 weeks. C and E represent structure of animals treated with 
CCl4 for 8 weeks. White arrows point collagen distribution in the liver. 
Magnification, 25 x. Black arrows indicate monocyte infiltration. Magnification, 
x 400. 
 
3.2 Effect of liver fibrosis on efficiency of hydrodynamic gene delivery  
A standard HGD from the tail vein was performed using 7.5% body weight as injection volume 
and DNA concentration of 10 µg/ml. Animals were sacrificed 9 hrs after hydrodynamic injection 
of pCMV-Luc and the liver samples were collected. Figure 2A shows luciferase activity at 3.5 x 
108 RLU/mg of proteins in olive oil treated control animals compared to 1.0 x 107 RLU/mg in 
animals treated with CCl4 for 4 weeks. In the 8-week treated groups, the luciferase activity was 
1.4 x 109 RLU/mg for control, and 6.0 x 105 for CCl4-treated animals. The level of luciferase 
gene expression in CCl4 treated animals is 35 folds lower than that of control animals in CCl4 
treated animals for 4 weeks, and 2,320 folds lower in animals treated with CCl4 for 8 weeks. 
*
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Figure 2. Level of Luciferase Gene Expression in Rat Liver. Animals were 
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hydrodynamically transfected with pCMV-Luc plasmid DNA (10 µg/ml) and 
sacrificed 9 hr later. Liver samples were collected and luciferase activity determined 
using luciferase assay. Open columns represent level of luciferase activity in liver of 
control animals treated with olive oil, and the solid columns represent that of animals 
treated with CCl4. Standard bars represent SD of the average value from 3-5 animals. 
*, p<0.05; **, p<0.01. 
 
 
To examine whether the reduction of luciferase gene expression in fibrotic liver is correlated to 
the amount of plasmid delivered to the liver cells, we performed quantitative PCR with liver 
samples collected from control and CCl4 treated (8 weeks) animals 9 hr post HGD. Table 1 
summarizes the copy number of pCMV-Luc plasmids in 1 µg of extracted DNA from the liver. 
There are approximately 1.84 x 106 copies/ µg of extracted DNA in control animal compared to 
1.54 x 104 copies/µg of DNA in fibrotic liver, an approximately 120-fold reduction. In addition, 
real-time q-PCR was performed to examine whether the reduction in luciferase expression is 
correlated to the mRNA level. Compared to that of control liver, luciferase mRNA per µg of total 
RNA in CCl4 treated rats (8 weeks) decreased by 572 folds. A rough calculation of transcription 
index (total mRNA divided by the copy number of pCMV-Luc plasmid) reveals 5-fold reduction 
in fibrotic liver, suggesting that in addition to a decrease in delivering plasmid DNA to cells in 
the fibrotic liver, the intracellular environment of fibrotic liver may also play a role in 
determining the overall level of reporter gene expression.  
 
Table 1. Relative Amount of Plasmid DNA and Luciferase mRNA in the Liver of 
Hydrodynamically Transfected Animals.* 
 
1.101.68 x 104 ± 1.54 x 1041.54 x 104 ± 1.15 x 104Fibrotic liver 
(CCl4, 8 wks)
5.239.63 x 106 ± 1.16 x 1061.84 x 106 ±8.81 x 105Control 
(olive oil, 8 wks)
Transcription Index 
(mRNA/plasmid DNA)
Luciferase mRNA in 1 
µg of total RNA
Number of pCMV-Luc 
plasmid in 1 µg of total DNA
Liver Sample
 
*Animals were hydrodynamically transfected with pCMV-Luc plasmid DNA (10 
µg/ml) and sacrificed 9 hr later. Total DNA or RNA were extracted from the liver and 
used for determination of copy number of pCMV-Luc plasmids by q-PCR and for 
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estimation of total amount of luciferase mRNA by q-RT-PCR. 
 
3.3 Effect of liver fibrosis on HGD-induced structural changes  
Previous reports showed that HGD induces structural change in the liver, including enlargement 
of the endothelial fenestrae and stretching of liver lobules,16, 19 which are believed to be the 
critical elements of HGD. To examine whether the structural impact of the procedure was 
weakened on fibrotic liver, we performed hydrodynamic injection of the fixative solution directly 
into the anesthetized rats with or without liver fibrosis. The liver samples were collected and 
subjected to scanning and transmission electron microscopy (SEM and TEM). Figure 3 shows 
sinusoidal structure of the liver from control animals receiving a slow infusion (Figure 3A) or 
hydrodynamic injection (Figure 3B), respectively. Enlarged fenestrae (Figure 3B) are readily 
visible in hydrodynamically injected control animal. However, in animals with liver fibrosis 
(Figures 3C and 3D), no obvious changes in sinusoids are observed with (Figure 3D) or without 
(Figure 3C) hydrodynamic injection. Compared to that of control animals (Figure 3A), liver 
sinusoids in fibrotic liver is significantly less fenestrated with no or smaller pores (Figure 3C).  
 
Figure 3E is an image of TEM from the liver of a control animal infused slowly with the same 
volume of fixative solution. The thin layer of endothelium, the space of Disse, the microvilla of 
the hepatocytes, and the fenestrae are seen. Upon hydrodynamic injection, different structures 
were seen in the liver of control animal (Figure 3F). The sinusoidal endothelium became 
discontinuous due to enlargement of fenestrae (Figure 3F), and the space of Disse became 
expanded (Figure 3F). Vesicle-like structures are seen in the hepatocytes surrounding the 
sinusoids of control animal after hydrodynamic injection. In contrast, the space of Disse in 
fibrotic liver appears smaller (Figure 3G), and the sinusoids were not affected by the 
hydrodynamic injection in CCl4-treated animals (Figures 3G, 3H), although moderately enlarged 
fenestrae could be occasionally observed (Figure 3H). The SEM and TEM data suggest that the 
hydrodynamic procedure that could result in efficient plasmid delivery in healthy liver was less 
capable of inducing necessary structural changes in fibrotic liver. 
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Figure 3. Electron Microscopic Images of the Liver. CCl4 treated (8 weeks) 
animals were either slowly infused or hydrodynamically injected into the inferior 
vena cava with 2.5% glutaraldehyde in PBS in a volume equals to 10% body 
weight. Liver samples were collected, fixed and sectioned for SEM (A-D) and 
TEM (E-H) examination. A, C, E and F are representative structures of animals 
receiving slow infusion, and B, D, F, G are structures of hydrodynamically 
injected animals. H, hepatocyte; F, fenestrae; SE, sealed endothelium; EF, 
enlarged fenestrae; S, sinusoid; SOD, space of Disse; RBC, red blood cell; MV, 
microvilla. Magnification, x 10,000. 
 
 
3.4 Hepatocytes were less permeabilized by hydrodynamic injection in CCl4-treated liver. 
HGD generates transient defects on hepatocyte membrane which was reflected by elevation of 
serum concentration of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).11, 
13-14 The release of liver specific enzymes from hepatocytes is an indicator for intracellular gene 
transfer into hepatocytes. Serum concentration of ALT and AST was determined 9 hrs after 
hydrodynamic injection. Figure 4 shows significant increase of ALT and AST induced by 
hydrodynamic injection in control animals, compared to very limited increase in CCl4-treated 
animals, suggesting a reduced impact of hydrodynamic procedure on peameabilizing hepatocytes 
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in fibrotic liver. 
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Figure 4. Effect of Hydrodynamic Injection on the Serum 
Concentration of ALT and AST. Serum samples from hydrodynamically 
treated animals were collected 9 hr post injection and ALT and AST 
concentration determined. A and B represent serum level of ALT and AST 
in olive oil treated control animals (open bar) or CCl4 treated animals (solid 
bar), respectively.   
 
3.5 Fibrotic liver is highly resistant to the flow-through of hydrodynamically injected 
solution across the liver. 
Additional efforts were made to understand different response between the normal and fibrotic 
liver to HGD. Previous reports showed that an elevated vascular pressure across the entire liver 
is essential for HGD and the pressure generated by a tail vein injection is the same in inferior 
vena cava (IVC) and portal vein (PV).16, 19 To examine whether the fibrotic liver has different 
pressure profile compared to control animals, I measured the vascular pressure in IVC and PV 
upon hydrodynamic injection to the tail vein. As expected, hydrodynamic injection induced 
moderate increase in IVC pressure (20 mmHg) in control liver which was the same as that of PV 
pressure in control animal (Figure 5), reflecting an unrestricted vasculature that allows pass-
through of injected solution across the entire liver.16 However, the IVC pressure in fibrotic liver 
upon hydrodynamic injection was around 400 mmHg and the PV pressure was not elevated to 
the same degree (~20 mmHg). These results suggest that the fibrotic liver is highly resistant to 
retrograde flow across the liver of the hydrodynamically injected solution. 
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Figure 5. Effect of Hydrodynamic Injection on Vascular Pressure of the 
Inferior Vena Cava and Portal Vein. Pressure transducer was inserted 
into the inferior vena cava or portal vein before hydrodynamic injection 
was performed with needle insertion at the lower end of inferior vena cava. 
The peak pressure was recorded and plotted. Open bars represent pressure 
in inferior vena cava and solid bars represent the pressure in the portal vein. 
The value represent the average + SD, n=3. 
 
3.6 Hydrodynamic gene delivery is safe in animals with fibrotic liver. 
The profound increase in IVC pressure during hydrodynamic injection in CCl4-treated rats raised 
safety concern of the HGD in animals with liver fibrosis. Careful examination of all internal 
organs including the liver, kidney, heart, lung, and spleen was done for all animals used in the 
study and no liver rupture or organ damage was seen in any of the animals. No internal bleeding 
or other abnormality of the internal organs were noticed when the animals were sacrificed for 
liver harvesting. No obvious necrosis of the parenchyma cells were observed in the CCl4-treated 
livers 9 hrs after hydrodynamic injection.  
 
Electrocardiogram (ECG) was performed to examine whether the systemic hydrodynamic 
injection through tail vein would affect the heart function in animals with fibrotic liver. 
Compared to ECG before the injection, the heart rate in CCl4-treated rats started to decrease 
immediately after the hydrodynamic injection (Figure 6). The P, Q, R, S, T waves reflecting the 
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atrium and ventricle activity showed irregularity a few minutes after HGD, presumably due to 
temporary inability to pump out the injected DNA solution from the IVC. Nevertheless, these 
waves returned to normal 8 min later (Figure 6). Overall, the cardiac disturbance by 
hydrodynamic injection in CCl4-treated rats was not severer than that observed in healthy rats.14  
Before injection
During injection
Post injection
 
Figure 6. Impact of Hydrodynamic Injection on Cardiac Function of 
CCl4-treated Rats. Electrocardiogram was recorded during hydrodynamic 
tail vein injection in an anesthetized rat which had been treated with CCl4 for 
8 weeks. The ECG spectra before, during and post hydrodynamic injection 
are shown in 5-sec segments. 
 
The concentrations of serum components were measured before and 9 hrs after hydrodynamic 
injection, and the results were summarized in Table 2. With the exception of a slight elevation of 
ALT and AST post injection (Figure 4), the concentrations of other serum components are very 
similar before and after 9 hr after hydrodynamic injection. In addition, the concentrations of the 
serum components in CCl4-treated rats were comparable to those in control animals, suggesting 
that the HGD procedure did not induce severer organ and blood disturbance in animals with liver 
fibrosis. 
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Table 2. Effect of Hydrodynamic Injection on Serum Biochemistry* 
Serum Concentration
Fibrotic (CCl4 8 wks)Control (olive oil, 8 wks)Fibrotic (CCl4 4 wks)Control (olive oil, 4 wks)
Serum 
Components
AfterBeforeAfterBeforeAfterBeforeAfterBefore
20.0±6.1
11.7±6.1
9.5±2.1
102.7±2.3
6.9±2.9
142.0±4.6
147.7±40.5
0.57±0.06
17.7±3.2
0.10±0.00
240.3±14.5
<3
2.1±0.2
3.3±0.0
5.4±0.2
24.0±1.4
9.6±1.2
9.5±0.0
103.0±2.8
5.9±2.0
141.5±0.7
231.0±77.8
0.50±0.00
20.0±12.7
0.15±0.07
267.0±36.8
<3
2.0±0.8
3.7±0.7
5.7±1.5
14.5±2.1
13.3±2.2
9.7±0.1
106.0±7.1
6.2±0.3
153.0±5.7
127.5±54.5
0.65±0.07
18.0±7.1
0.10±0.00
226.7±86.4
<3
2.1±0.1
3.0±0.3
4.9±0.5
24.5±0.7
10.1±0.0
9.5±0.2
101.0±0.0
6.7±0.4
141.0±0.0
173.5±10.6
0.80±0.28
27.0±0.0
0.10±0.00
253.7±22.3
<3
2.1±0.2
3.8±0.2
5.9±0.4
2.1 ± 0.22.5 ± 0.11.9 ± 0.33.1 ± 0.0
Globulin (g/dL)
<3 <3<3<3
Gamma-GT 
(U/L)
10.9±0.810.1±0.49.3±0.710.1±0.7Ca2+ (mmol/L)
9.1±3.08.0±0.79.3±3.9 8.8±0.9PO43- (mmol/L)
25.0±5.321.7±4.026.0±0.021.0±0.0HCO3- (mmol/L)
106.5±0.7100±1.7105.0±0.097.0±1.6Cl- (mmol/L)
9.4±2.46.0±0.45.1±0.26.9±0.3K+ (mmol/L)
145.0±1.4 143.3±1.5140.0±1.4140.0±1.8Na+ (mmol/L)
138.0±10.2117.7±32.7186.5±46.0121.0±0.0Glucose (mg/dL)
0.60±0.000.73±0.060.57±0.150.55±0.21
Creatinine
(mg/dL)
18.0±2.725.0±2.017.3±3.123.5±0.7BUN (mg/dL)
0.27±0.060.30±0.350.10±0.060.20±0.10
Total Bilirubin
(mg/dL)
275.5±20.5217.7±122.5169.7±31.6133.5±21.9
Alkaline 
Phosphatase
(U/L)
3.0±0.23.9±0.53.3± 0.24.4±0.2
Albumin (g/dL)
5.1±0.46.4±0.65.2±0.57.5±0.2
Total Protein 
(g/dL)
 
*Sera were obtained from rats before and 9hr after hydrodynamic injection of 
plasmid solution and subjected to automated analysis for the concentration of 
serum components. Abbreviations: Gamma-GT, gamma-glutamic 
aminotransferase; BUN, blood urea nitrogen; Na+, sodium ion; K+, potassium 
ion; Cl-, chloride ion; Ca2+, calcium ion; PO43-, phosphate ion; HCO3-, 
bicarbonate ion. 
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4.0 DISCUSSION 
The present work shows that HGD, although safe, is less effective in gene delivery to fibrotic 
liver as demonstrated by lower level of reporter gene expression (Figure 1), reduced copy 
number of plasmid DNA and lower amount of mRNA (Table 1). The microscopic studies suggest 
that the reduced efficiency of HGD in fibrotic liver is caused by accumulated collagen fibers at 
lobular boundary that limits the expansion of hepatic lobule (Figure 1) and permeabilization of 
plasma membrane of hepatocytes (Figure 4). Thickened endothelium and reduced liver fenestrae 
in highly fibrotic liver (CCl4 treated for 8 weeks) (Figure 3) also play important role in 
preventing the expansion and enlargement of fenestrae that, otherwise, provides the access of 
plasmid DNA to space of Disse and the parenchyma cells. 
 
Evidently, the effectiveness of HGD appears reversibly proportional to the severity of liver 
fibrosis (Figure 2). For animals treated with CCl4 for 4 weeks, the reduction in luciferase gene 
expression was 35 about folds lower than that of control animals compared to greater than 2,000 
folds of the fibrotic liver in advanced stage (CCl4 treated for 8 weeks). While the progressive 
effect of the liver fibrosis on the efficiency of HGD suggests that it is more desirable to apply 
HGD as earlier as possible during fibrogenesis, these results also suggest that there are cells in 
fibrotic liver that are still hydrodynamically transfectable because some reporter gene expression 
was detected. Effort in identifying the unique nature of these cells or liver structure in favor of 
HGD in fibrotic liver may yield new information toward developing new strategies for improved 
efficiency of HGD. In addition, strategies that would reduce the level of collagen fibers in the 
liver would be helpful in achieving higher effectiveness of HGD.  
 
The transcription index (total mRNA/copy number of plasmid) is an interesting parameter 
because it indicates efficacy of gene delivery and transcription in the liver. Our results (Table 1) 
indicate that the transcription index decreased about 5 folds in fibrotic liver, suggesting that the 
condition in normal liver must offer cells advantage for gene expression or cells in fibrotic liver 
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disadvantage for gene expression. Considering that fibrosis is a pathological condition of the 
liver and associated with severe inflammation, the lower transcription index seen in fibrotic liver 
could be the result of down regulation of reporter gene expression by higher concentration of 
proinflammatory factors such as IFN-γ,20-21 which are over expressed in the injured liver as part 
of the defending and repairing mechanism.22 A prudent strategy to enhance gene expression in 
fibrotic liver cells is to include into the plasmid of the elements that would avoid the 
inflammation-mediated down regulation, or/and the elements that would enhance gene 
expression by pathological factors.  
 
Effectiveness of HGD to liver is dependent on the fenestrated vasculature and the elasticity of 
the liver. This is because the expansion and permeabilization of the blood vasculature and the 
plasma membrane of the hepatocytes are consequence of the procedure and essential for plasmid 
DNA to reach the space of Disse and enter the hepatocytes.16, 19 Microscopy study shows 
(Figures 1 and 3) obvious morphological change of the sinusoids and lobular structure in the 
fibrotic liver with significant decrease of fenestrae in both density and diameter, and 
accumulation of protein fibers at the boundary of each lobule, making the sinusoids more 
resistant to hydrodynamic pressure and less elastic for expansion. Also, the morphological 
changes were associated with resistance to the flow-through of injected DNA solution across the 
liver (Figure 5) and a decrease in gene delivery efficiency. The fact that effective gene transfer to 
skeletal muscle has been achieved in pigs using a computer–controlled injection device23 
suggests that it may be possible to improve gene delivery efficiency to fibrotic liver by 
increasing the injection speed and injection volume. Alternatively, localized injection into the 
hepatic vein employing the technique of image-guided hydrodynamic gene delivery24 could 
enhance gene delivery efficiency.   
 
Despite the reduced effectiveness, the HGD procedure appeared to be safe in animals with 
fibrotic liver. No obvious cell death in the CCl4-treated liver was observed after HGD (Figures 
1D-1F) and the changes in ECG and serum composition after hydrodynamic injection were 
similar between control and CCl4-treated animals. An acute overload of large volume of DNA 
solution in animals appears very transient and did not cause additional cardiac irregularity in 
fibrotic rats compared to that of control animals. 
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5.0 SUMMARY AND CONCLUSION 
 
In summary, as evidenced by excessive accumulation of extracellular matrix and morphological 
change of the sinusoids and hepatic lobules, we have shown in this study that progressive liver 
fibrosis can be developed by weekly injection of CCl4. The accumulation of protein fibers 
induced structural and morphological change of the liver and is directly responsible for reduced 
efficacy of HGD. As far as the application of HGD to gene therapy of liver fibrosis is concerned, 
it is more desirable to start the treatment as early as possible when the liver remains its normal 
structure. Alternatively, more research is needed to explore the possibility of either removing the 
protein fibers or employing higher hydrodynamic pressure to achieve higher gene delivery 
efficiency. In this respect, we believe that additional research could result in new information 
based on which a new and more effective method of gene delivery can be developed for gene 
therapy on a devastating disease that affects millions of people each year.  
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